P. Bohlen

发表

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability.

M. Corada, L. Zanetta, F. Orsenigo, 2002, Blood.

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.

N. Fusenig, P. Bohlen, Silvia Vosseler, 2005, Cancer research.

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

S. Rafii, D. Hicklin, P. Bohlen, 2005, The Journal of clinical investigation.

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

M. Westphal, P. Bohlen, K. Lamszus, 2001, Cancer research.

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

P. Bohlen, P. Kussie, A. Kiselyov, 2009, Bioorganic & medicinal chemistry.

Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis

S. Rafii, R. Crystal, F. Liao, 2004, Nature Medicine.

Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase.

D J Jolly, A C Esty, T Friedmann, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

D. Hicklin, P. Bohlen, W. Grizzle, 2002, International journal of radiation oncology, biology, physics.

Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI), but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis 1

P. Bohlen, Yan Wu, M. Gougerot-Pocidalo, 2003, The Journal of Immunology.

Gonadocrinins: Peptides in Ovarian Follicular Fluid Stimulating the Secretion of Pituitary Gonadotropins*

N. Ling, R. Guillemin, P. Bohlen, 1981 .

Evidence for FGF-like growth factor in adult bovine retina: analogies with EDGF I.

Y. Courtois, P. Bohlen, J. Courty, 1986, Biochemical and biophysical research communications.

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Peter Bohlen, Dipa Patel, Xiaoqiang Kang, 2004, Human antibodies.

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

P. Bohlen, Zhen-ping Zhu, Haifan Zhang, 2002, International journal of cancer.

Immunohistochemical detection of growth hormone-releasing factor in brain

F. Bloom, N. Ling, R. Guillemin, 1983, Nature.

Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

D. Hicklin, P. Bohlen, S. Hirakawa, 2004, Blood.

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

F. Liao, D. Hicklin, P. Bohlen, 2002, Cancer research.

Erratum: Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor (Biochemistry (April 22, 1997) 36:16 (4782-4791))

R. Powers, D. Kitchen, P. Bohlen, 1997 .

The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.

P. Bohlen, T. Hartman, Jeff G. Wang, 2005, Endocrinology.

Advances in Brief Inhibition of Glioma Angiogenesis and Growth in Vivo by Systemic Treatment with a Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor-21

M. Westphal, P. Bohlen, K. Lamszus, 2001 .

Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea.

P. Bohlen, T. Hartman, M. Sauer, 2001, Microvascular research.

ratssecretion and sympathetic outflow in Acidic fibroblast growth factor activates

H. Berthoud, P. Bohlen, Y. Oomura, 2013 .

Isolation of fibroblast growth factor from bovine adrenal gland: physicochemical and biological characterization.

P. Bohlen, D. Gospodarowicz, G. Lui, 1986, Endocrinology.

Corpus luteum angiogenic factor is related to fibroblast growth factor.

P. Bohlen, D. Gospodarowicz, G. Lui, 1985, Endocrinology.

Isolation and characterization of an endogenous C-terminal fragment of the alpha-neo-endorphin/dynorphin precursor from bovine caudate nucleus

P. Bohlen, C. Evans, J. Barchas, 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey.

P. Bohlen, M. Ferin, R. Zimmermann, 2002, Endocrinology.

Signaling and Inhibits Human Tumor Growth Growth Factor I Receptor Blocks Ligand-Dependent A Fully Human Monoclonal Antibody to the Insulin-Like Updated

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2003 .

Monoclonal antibody strategies to block angiogenesis.

D. Hicklin, P. Bohlen, L. Witte, 2001, Drug discovery today.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Blood.

Advances in Brief Inhibition of Vascular Endothelial Growth Factor-induced Receptor Activation with Anti-Kinase Insert Domain-containing Receptor Single-Chain Antibodies from a Phage Display Library

Zhenping, Zhen-ping, Zhu, 2006 .

Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*

P. Bohlen, Zhen-ping Zhu, P. Kussie, 2000, The Journal of Biological Chemistry.

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

P. Bohlen, K. Persaud, Z. Zhu, 1999, Journal of immunological methods.

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

D. Hicklin, P. Bohlen, X. Jimenez, 1999, Cancer letters.

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

S. Rafii, K. Hattori, P. Bohlen, 2003, Leukemia.

Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Leukemia & lymphoma.

Vascular endothelial growth factor receptor 2–mediated angiogenesis is essential for gonadotropin-dependent follicle development

P. Bohlen, T. Hartman, M. Sauer, 2003 .

Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development.

P. Bohlen, T. Hartman, M. Sauer, 2003, The Journal of clinical investigation.

An improved method for the purification of human insulin-like growth factors I and II.

P. Bohlen, J. Shively, P. Petrides, 1986, Endocrinology.

K / BxN Model of Rheumatoid Arthritis VEGF-RII , Suppresses Joint Destruction in Factor Receptor I ( VEGF-RI ) , but not Blockade of Vascular Endothelial Growth

P. Bohlen, Yan Wu, M. Gougerot-Pocidalo, 2003 .

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.

P. Bohlen, S. Hirakawa, M. Detmar, 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.

P. Bohlen, Zhen-ping Zhu, L. Witte, 2002, Current cancer drug targets.

Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion

N. Ling, R. Guillemin, L. Mandarino, 1981, Nature.

ISOLATION AND CHARACTERIZATION OF RAT HY POTH AL AM IC SOM ATOST AT IN-14

N. Ling, P. Bohlen, P. Brazeau, 1981 .

Inhibition of Glioblastoma Angiogenesis and Invasion by Combined Treatments Directed Against Vascular Endothelial Growth Factor Receptor-2, Epidermal Growth Factor Receptor, and Vascular Endothelial-Cadherin

M. Westphal, P. Bohlen, C. Eckerich, 2005, Clinical Cancer Research.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Peter Bohlen, Dan Lu, D. Hicklin, 2003, Cancer research.

VEGF‐A promotes tissue repair‐associated lymphatic vessel formation via VEGFR‐2 and the α1β1 and α2β1 integrins

P. Bohlen, S. Hirakawa, M. Detmar, 2004 .

A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity*

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2005, Journal of Biological Chemistry.

Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody*

P. Bohlen, Zhen-ping Zhu, Haifan Zhang, 2004, Journal of Biological Chemistry.

Solid phase synthesis of somatostatin-28.

N. Ling, R. Guillemin, P. Bohlen, 1980, Biochemical and biophysical research communications.

Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography.

Fabian Kiessling, Stefan Delorme, Peter Bohlen, 2003, Cancer research.

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1

A. Luttun, P. Carmeliet, H. Dvorak, 2002, Nature Medicine.

Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys.

Peter Bohlen, H. Berthoud, P. Bohlen, 2007, American journal of physiology. Endocrinology and metabolism.

rodents and monkeys cause potent but reversible hypophagia and weight loss in Monoclonal antibody antagonists of hypothalamic FGFR 1

H. Berthoud, P. Bohlen, O. McGuinness, 2007 .

Monoclonal antibody therapeutics and apoptosis

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2003, Oncogene.

Cloning and functional expression of a human heparanase gene.

P. Bohlen, S. Patel, P. Kussie, 1999, Biochemical and biophysical research communications.

Somatostatin-28 [1-12]-like peptides.

J. Morrison, N. Ling, R. Guillemin, 1985, Advances in experimental medicine and biology.

angiogenesis without side effects on endothelial permeability cadherin inhibits tumor - A monoclonal antibody to vascular endothelial

M. Corada, L. Zanetta, F. Orsenigo, 2013 .

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.

F. Liao, D. Hicklin, P. Bohlen, 2005, Blood.

Inhibition of the vascular endothelial cell (VE)-specific adhesion molecule VE-cadherin blocks gonadotropin-dependent folliculogenesis and corpus luteum formation and angiogenesis.

F. Liao, P. Bohlen, M. Sauer, 2005, Endocrinology.

Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability.

M. Corada, F. Breviario, M. Lampugnani, 2001, Blood.

Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis

D. Hicklin, P. Bohlen, A. Hooper, 2002, The Journal of experimental medicine.

Basic FGF Treatment of Endothelial Cells Down-regulates the 85-KDa TGFβ Receptor Subtype and Decreases the Growth Inhibitory Response to TGF-β1

P. Bohlen, B. Terman, V. Fafeur, 1990 .

Transglutaminase forms midkine homodimers in cerebellar neurons and modulates the neurite-outgrowth response.

P. Bohlen, A. Seddon, S. Mahoney, 1996, Biochemical and Biophysical Research Communications - BBRC.

Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase.

P. Bohlen, T. Friedmann, H. Okayama, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Peter Bohlen, Gabriele Bergers, Shane K Green, 2002, Cancer research.

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Peter Bohlen, Robert S. Kerbel, S. Baruchel, 2000 .

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

S. Baruchel, D. Hicklin, P. Bohlen, 2000, The Journal of clinical investigation.

Isolation and amino-terminal sequence of a novel cellular growth inhibitor (inhibitory diffusible factor 45) secreted by 3T3 fibroblasts.

P. Bohlen, C. Blat, G. Chatelain, 1989, The Journal of biological chemistry.

Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.

L. Zanetta, F. Liao, D. Hicklin, 2000, Cancer research.

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Peter Bohlen, Dan Lu, D. Hicklin, 2005, Molecular Cancer Therapeutics.

Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.

N. Fusenig, D. Hicklin, P. Bohlen, 2005, The American journal of pathology.

Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.

R. Jain, Y. Boucher, D. Hicklin, 2001, Cancer research.

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

S. Rafii, D. Hicklin, P. Bohlen, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

S. Rafii, R. Crystal, Z. Werb, 2002, Nature Medicine.

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

D. Hicklin, P. Bohlen, Y. Li, 1999, Cancer research.

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

D. Hicklin, P. Bohlen, R. Kerbel, 2001, Cancer research.

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

Barbara Mayer, Peter Bohlen, Shane K Green, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

D. Hicklin, P. Bohlen, Z. Zhu, 1998, Cancer research.

Cloning, expression, and purification of mouse heparanase.

P. Bohlen, P. Kussie, D. Ludwig, 2002, Protein expression and purification.

In situ hybridization histochemistry for the analysis of gene expression in the endocrine and central nervous system tissues: A 3‐year experience

B. Bloch, E. Normand, P. Bohlen, 1986, Journal of neuroscience research.

Detection of the messenger RNA coding for preproenkephalin A in bovine adrenal by in situ hybridization

F. Bloom, B. Bloch, P. Bohlen, 1984, Regulatory Peptides.

Gonadostatins and Gonadocrinin: Peptides from the Gonads Regulating the Secretion of Gonadotropins

N. Ling, R. Guillemin, P. Bohlen, 1981 .

Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity*

Peter Bohlen, Dan Lu, P. Bohlen, 2003, Journal of Biological Chemistry.

The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma

S. Rafii, D. Hicklin, P. Bohlen, 2006, International journal of cancer.

Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.

Wolfhard Semmler, Fabian Kiessling, Stefan Delorme, 2004, Neoplasia.

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.

Peter Bohlen, Dan Lu, P. Bohlen, 2001, Cancer research.

Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2008 .

Microisolation and Sequence Analysis of Human Epidermal Growth Factor

P. Bohlen, P. Petrides, F. Esch, 1987 .

cDNA cloning, chromosomal mapping, and expression analysis of human VE-Cadherin-2

D. Hicklin, P. Bohlen, E. Dejana, 2000, Mammalian Genome.

Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene.

P. Bohlen, D. Ludwig, L. Witte, 2001, Gene.

Isolation and characterization of the bovine hypothalamic corticotropin-releasing factor.

N. Ling, R. Guillemin, P. Bohlen, 1984, Biochemical and biophysical research communications.

Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells

S. Rafii, P. Bohlen, S. Shmelkov, 2006, Leukemia.

Di-diabody: a novel tetravalent bispecific antibody molecule by design.

Peter Bohlen, Dan Lu, P. Bohlen, 2003, Journal of immunological methods.

Advances in Brief Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts 1

R. Jain, Y. Boucher, D. Hicklin, 2000 .

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

S. Rafii, D. Hicklin, P. Bohlen, 2005, Cancer research.

Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.

D. Hicklin, P. Bohlen, Yiwen Li, 2003, Current molecular medicine.